Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00954356 · ClinicalTrials.gov registry record · Phase 2

Safety and Efficacy Study of XPF-001 to Treat Pain Following Wisdom Tooth Extraction

A Phase 2 study of Dental Pain, sponsored by Xenon Pharmaceuticals.

Completed
Registry status
Phase 2
Development phase
61
Enrollment target
1
Study location

NCT00954356 is a Phase 2 study of Dental Pain that has completed, run by Xenon Pharmaceuticals. The registered enrollment target is 61 participants, below the 235-participant average among 6 other Dental Pain trials with a reported enrollment target (74% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00954356, a Phase 2 study of Dental Pain, has completed, sponsored by Xenon Pharmaceuticals.

COMPLETED
Registry status
Phase 2
Development phase
61 participants
Enrollment target
1
Study location

Study Summary

The purpose of this trial is to determine if XPF-001 is effective for the treatment of pain following third-molar/wisdom tooth extraction.

Conditions Studied

Interventions

  • DRUG placebo
  • DRUG XPF-001

Study Locations (1)

Utah

  • Jean Brown Research - Salt Lake City

Trial Details

FieldValue
Enrollment Target 61 participants
Start Date 2009-09
Est. Completion 2009-12
Phase Phase 2

Sponsor

Xenon Pharmaceuticals

13 total trials

What the Registry Record Tells You About NCT00954356

The ClinicalTrials.gov registry entry for NCT00954356 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 61 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 235-participant average among 6 other Dental Pain trials with a reported enrollment target (74% lower). The listed sponsor is Xenon Pharmaceuticals, which has 13 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Dental Pain appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.

NCT00954356 reports 1 study location spanning 1 distinct geographic area - top geographies include Utah.

Frequently Asked Questions

What is clinical trial NCT00954356 about?

NCT00954356 is a clinical study titled "Safety and Efficacy Study of XPF-001 to Treat Pain Following Wisdom Tooth Extraction". The purpose of this trial is to determine if XPF-001 is effective for the treatment of pain following third-molar/wisdom tooth extraction.

What is the current status of trial NCT00954356?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 61 participants. The study started on 2009-09. Estimated completion is 2009-12.

What conditions does trial NCT00954356 study?

This clinical trial studies the following conditions: Dental Pain.

What interventions are being tested in trial NCT00954356?

The interventions under investigation include: placebo (DRUG), XPF-001 (DRUG).

Who is sponsoring clinical trial NCT00954356?

This trial is sponsored by Xenon Pharmaceuticals, which has 13 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00954356 being conducted?

This trial has 1 study location across Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Dental Pain

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.